Graeber Manuel B, Müller Ulrich
Department of Neuropathology, Division of Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.
Neurogenetics. 2003 Aug;4(4):157-62. doi: 10.1007/s10048-003-0155-y. Epub 2003 Jul 26.
Dementia with Lewy bodies (DLB) was first recognized as a clinicopathological entity about 20 years ago. It is the second most-common degenerative dementia after Alzheimer's disease. Clinically, DLB differs from Alzheimer's disease in that disease symptoms are prone to fluctuate and patients often suffer from visual hallucinations, while short-term memory is relatively preserved. As many as 70% of patients have parkinsonism and up to 50% are sensitive to the extrapyramidal side effects of neuroleptic drugs. About 3 million Europeans will be affected by DLB in 2020 if no cure or effective treatment is found. This article reviews the current disease concept, as well as existing problems concerning classification and delineation of DLB from other conditions with dementia. The literature on genetic findings in this complex disease is critically discussed.
路易体痴呆（DLB）约在20年前首次被确认为一种临床病理实体。它是继阿尔茨海默病之后第二常见的退行性痴呆。临床上，DLB与阿尔茨海默病的不同之处在于，其疾病症状易于波动，患者常伴有视幻觉，而短期记忆相对保留。多达70%的患者患有帕金森症，高达50%的患者对抗精神病药物的锥体外系副作用敏感。如果找不到治愈方法或有效治疗手段，到2020年约有300万欧洲人将受DLB影响。本文综述了当前的疾病概念，以及DLB分类和与其他痴呆症鉴别方面存在的问题。对有关这种复杂疾病基因研究结果的文献进行了批判性讨论。
